Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy - PubMed (original) (raw)
Comparative Study
doi: 10.1002/ijc.10316.
Affiliations
- PMID: 11948484
- DOI: 10.1002/ijc.10316
Comparative Study
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy
Dietmar W Siemann et al. Int J Cancer. 2002.
Abstract
The utility of combining the vascular targeting agents 5,6-dimethyl-xanthenone-4 acetic acid (DMXAA) and combretastatin A-4 disodium phosphate (CA4DP) with the anticancer drugs cisplatin and cyclophosphamide (CP) was evaluated in experimental rodent (KHT sarcoma), human breast (SKBR3) and ovarian (OW-1) tumor models. Doses of the vascular targeting agents that led to rapid vascular shutdown and subsequent extensive central tumor necrosis were identified. Histologic evaluation showed morphologic damage of tumor cells within a few hours after treatment, followed by extensive hemorrhagic necrosis and dose-dependent neoplastic cell death as a result of prolonged ischemia. Whereas these effects were induced by a range of CA4DP doses (10-150 mg/kg), the dose response to DMXAA was extremely steep; doses < or = 15 mg/kg were ineffective and doses > or = 20 mg/kg were toxic. DMXAA also enhanced the tumor cell killing of cisplatin, but doses > 15 mg/kg were required. In contrast, CA4DP increased cisplatin-induced tumor cell killing at all doses studied. This enhancement of cisplatin efficacy was dependent on the sequence and interval between the agents. The greatest effects were achieved when the vascular targeting agents were administered 1-3 hr after cisplatin. When CA4DP (100 mg/kg) or DMXAA (17.5 mg/kg) were administered 1 hr after a range of doses of cisplatin or CP, the tumor cell kill was 10-500-fold greater than that seen with chemotherapy alone. In addition, the inclusion of the antivascular agents did not increase bone marrow stem cell toxicity associated with these anticancer drugs, thus giving rise to a therapeutic gain.
Copyright 2002 Wiley-Liss, Inc.
Similar articles
- Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126.
Siemann DW, Rojiani AM. Siemann DW, et al. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1512-7. doi: 10.1016/s0360-3016(02)03919-6. Int J Radiat Oncol Biol Phys. 2002. PMID: 12459379 - Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. Siim BG, et al. Cancer Chemother Pharmacol. 2003 Jan;51(1):43-52. doi: 10.1007/s00280-002-0529-0. Epub 2002 Nov 12. Cancer Chemother Pharmacol. 2003. PMID: 12497205 - Vascular-targeting therapies for treatment of malignant disease.
Siemann DW, Chaplin DJ, Horsman MR. Siemann DW, et al. Cancer. 2004 Jun 15;100(12):2491-9. doi: 10.1002/cncr.20299. Cancer. 2004. PMID: 15197790 Review. - Potential of DMXAA combination therapy for solid tumors.
Baguley BC, Wilson WR. Baguley BC, et al. Expert Rev Anticancer Ther. 2002 Oct;2(5):593-603. doi: 10.1586/14737140.2.5.593. Expert Rev Anticancer Ther. 2002. PMID: 12382527 Review.
Cited by
- Antitumor effects of combining docetaxel (taxotere) with the antivascular action of ultrasound stimulated microbubbles.
Goertz DE, Todorova M, Mortazavi O, Agache V, Chen B, Karshafian R, Hynynen K. Goertz DE, et al. PLoS One. 2012;7(12):e52307. doi: 10.1371/journal.pone.0052307. Epub 2012 Dec 20. PLoS One. 2012. PMID: 23284980 Free PMC article. - Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancer.
Wolfson E, Solomon S, Schmukler E, Goldshmit Y, Pinkas-Kramarski R. Wolfson E, et al. Cell Death Dis. 2018 Jan 19;9(2):47. doi: 10.1038/s41419-017-0067-7. Cell Death Dis. 2018. PMID: 29352243 Free PMC article. - Low Z target switching to increase tumor endothelial cell dose enhancement during gold nanoparticle-aided radiation therapy.
Berbeco RI, Detappe A, Tsiamas P, Parsons D, Yewondwossen M, Robar J. Berbeco RI, et al. Med Phys. 2016 Jan;43(1):436. doi: 10.1118/1.4938410. Med Phys. 2016. PMID: 26745936 Free PMC article. - Preclinical Activity of the Vascular Disrupting Agent OXi4503 against Head and Neck Cancer.
Bothwell KD, Folaron M, Seshadri M. Bothwell KD, et al. Cancers (Basel). 2016 Jan 7;8(1):11. doi: 10.3390/cancers8010011. Cancers (Basel). 2016. PMID: 26751478 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous